Page 17 - Read Online

Bozzetti et al. Neuroimmunol Neuroinflammation 2021;8:1-13 I http://dx.doi.org/10.20517/2347-8659.2020.26 Page 13

disorders. Brain 2019;142:1310-23.
72. Mariotto S, Gajofatto A, Batzu L, Delogu R, Sechi G, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of
seronegative cases. Neurology 2019;93:e1867-72.
73. Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica
and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016;87:897-905.
74. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, et al. Distinction between MOG antibody-positive and AQP4
antibody-positive NMO spectrum disorders. Neurology 2014;82:474-81.
75. Cobo-Calvo Á, Ruiz A, D’Indy H, Poulat AL, Carneiro M, et al. MOG antibody-related disorders: common features and uncommon
presentations. J Neurol 2017;264:1945-55.
76. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, et al. Clinical spectrum and IgG subclass analysis of anti-myelin
oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol 2017;264:2420-30.
77. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, et al; OFSEP and NOMADMUS Study Group. Clinical spectrum and prognostic
value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018;90:e1858-69.
78. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK
study. Brain 2017;140:3128-38.
79. Cobo-Calvo A, Vukusic S, Marignier R. Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity
in adults. Curr Opin Neurol 2019;32:459-66.
80. Mariotto S, Monaco S, Peschl P, Coledan I, Mazzi R, et al. MOG antibody seropositivity in a patient with encephalitis: beyond the
classical syndrome. BMC Neurol 2017;17:190.
81. Juryńczyk M, Jacob A, Fujihara K, Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical
considerations. Pract Neurol 2019;19:187-95.
82. López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, et al. Association of MOG-IgG serostatus with relapse after acute
disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-Associated disorders. JAMA Neurol 2018;75:1355-63.
83. de Mol CL, Wong Y, van Pelt ED, Wokke B, Siepman T, et al. The clinical spectrum and incidence of anti-MOG-associated acquired
demyelinating syndromes in children and adults. Mult Scler 2019;16:1352458519845112.
84. Cobo-Calvo A, Sepúlveda M, d’Indy H, Armangué T, Ruiz A, et al; REEM Group. Usefulness of MOG-antibody titres at first episode to
predict the future clinical course in adults. J Neurol 2019;266:806-15.
85. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both
important. Mult Scler 2017;23:182-4.
86. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical
CSF biomarker study. Neurology 2010;75:208-16.
87. Wang H, Wang C, Qiu W, Lu Z, Hu X, et al. Cerebrospinal fluid light and heavy neurofilaments in neuromyelitis optica. Neurochem Int
2013;63:805-8.
88. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein,
myelin/oligodendroglial glycoprotein, and 2’,3’-cyclic nucleotide 3’-phosphodiesterase in the CNS of adult rats. J Neurochem
1989;52:296-304.
89. Mariotto S, Farinazzo A, Monaco S, Gajofatto A, Zanusso G, et al. Serum neurofilament light chain in nmosd and related disorders:
comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status. Mult Scler J Exp Transl Clin
2017;3:2055217317743098.
90. Mariotto S, Ferrari S, Gastaldi M, Franciotta D, Sechi E, et al. Neurofilament light chain serum levels reflect disease severity in MOG-Ab
associated disorders. J Neurol Neurosurg Psychiatry 2019;90:1293-6.
91. Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, et al. Serum GFAP and neurofilament light as biomarkers of disease activity
and disability in NMOSD. Neurology 2019;93:e1299-311.
92. Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatr Dis Treat
2018;14:2241-54.